KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $348.0 million.

  • Bio-Rad Laboratories' Cost of Revenue rose 687.96% to $348.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 468.13%. This contributed to the annual value of $1.2 billion for FY2025, which is 469.01% up from last year.
  • Per Bio-Rad Laboratories' latest filing, its Cost of Revenue stood at $348.0 million for Q4 2025, which was up 687.96% from $309.6 million recorded in Q3 2025.
  • In the past 5 years, Bio-Rad Laboratories' Cost of Revenue ranged from a high of $348.0 million in Q4 2025 and a low of $279.4 million during Q1 2025
  • For the 5-year period, Bio-Rad Laboratories' Cost of Revenue averaged around $309.7 million, with its median value being $309.6 million (2021).
  • In the last 5 years, Bio-Rad Laboratories' Cost of Revenue skyrocketed by 2888.2% in 2021 and then tumbled by 1105.59% in 2024.
  • Bio-Rad Laboratories' Cost of Revenue (Quarter) stood at $334.3 million in 2021, then fell by 0.35% to $333.2 million in 2022, then dropped by 5.51% to $314.8 million in 2023, then grew by 3.43% to $325.6 million in 2024, then increased by 6.88% to $348.0 million in 2025.
  • Its Cost of Revenue was $348.0 million in Q4 2025, compared to $309.6 million in Q3 2025 and $306.3 million in Q2 2025.